CeaproTSXV: CZO

Ceapro announces 2004 financial results

· Issued by Ceapro via CNW
EDMONTON, April 27 /CNW/ - Ceapro Inc. (TSX-V: CZO) today released its
financial results for 2004. Several factors contributed to the net loss of
$398,000 in 2004, compared with net income of $442,000 last year. These
included the absence of revenues from the sale of royalties interest units (no
units were offered for sale), the occurrence of, specific, one-time legal and
consulting expenses that were unrelated to regular operations, slightly lower
product sales (including the reduced volume requirements from a major cosmetic
customer) and a shift in product mix resulting in lower margins, higher
general and administrative, royalty, and amortization expenses, a loss on
disposal of property and equipment, and a higher Canadian dollar.
"Overall, 2004 was a positive year for Ceapro," said Dr. Mark Redmond,
Ceapro's President and CEO. "We made significant advances in the area of our
diabetes diagnostic technology, which we have rebranded as CeaProve(TM). We
launched two new products and prototyped three new products for the cosmetics
and personal care industries. We developed seven new concepts for veterinary
therapeutic markets, three of which are proceeding through the development
phase with introductions planned for late 2005. We have also strengthened our
human and capital resources necessary to expand our production capacity to
meet the global demand for our products." Dr. Redmond continued, "The decline
in beta glucan sales was disappointing; however new formulations of beta
glucan, containing major enhancements to reduce shipping and storage costs,
were introduced in late 2004 and we are anticipating increased sales volumes
in 2005."

<<

HIGHLIGHTS

Revenue

$000s                                               2004    2003  Change
-------------------------------------------------------------------------
Product sales
  Active ingredients                               1,338   1,680    (20%)
  Veterinary therapeutic products                    619     538     15%
-------------------------------------------------------------------------
                                                   1,957   2,218    (12%)
Royalties, licenses, and product development         463     206    125%
-------------------------------------------------------------------------
Total revenues                                     2,420   2,424       -
-------------------------------------------------------------------------

Total revenues, which include product sales and royalties, licenses, and
product development fees, were comparable to last year, at $2.4 million. The
overall volume of sales increased slightly in 2004 but the rising Canadian
dollar negatively impacted recorded revenues.

General and Administrative

$000s                                               2004    2003  Change
-------------------------------------------------------------------------
Salaries and benefits                                265     267
Consulting                                            56      55
Travel, accommodation, meals and entertainment        30      31
Computer systems and support                          24       2
Insurance                                             99      80
Rent                                                  49      40
Board of Directors compensation                       65      51
Investor relations                                    97      78
Legal                                                 36      33
Other                                                112     120
-------------------------------------------------------------------------
Total general and administrative expenses            833     757     10%
-------------------------------------------------------------------------

General and administrative expenses (G&A) rose 10% due to several
factors. Additional computer systems support costs were incurred for planning
and implementation for Ceapro's redeveloped website and upgrading internal
computer network systems required to support our business. Higher insurance
costs resulted from an increase in coverage to accommodate growth in our
business, provide adequate coverage, and an overall premium rate increase
versus last year. Increased volume and costs associated with required
information reporting and shareholder mailings, and developmental activities
undertaken for investor relations communications strategy and materials
increased investor relations and stock listing fees. The Board of Directors'
compensation increased as a result of changing to a fee-based compensation
structure from a stock-based compensation structure. During the year all
Directors exercised stock options in amounts sufficient to fund the fees
payable to them for the year. Ceapro's rent also increased as a direct result
of the relocation of the offices to new space within the Research Transition
Facility located on the University of Alberta Campus.

Sales and Marketing

$000s                                               2004    2003  Change
-------------------------------------------------------------------------
Salaries and benefits                                 82     133
Consulting                                            33      16
Travel, accommodation, meals and entertainment         9      80
Other                                                  7       2
-------------------------------------------------------------------------
Total sales and marketing expenses                   131     231    (43%)
-------------------------------------------------------------------------

Sales and marketing expenses declined 43% largely due to a reduction of
time spent on marketing activities by senior management and scientific
personnel, lower travel and related. Throughout the year, senior management
and scientific personnel were required to spend significant time renewing,
refreshing and reformulating existing products and were not as available to
support the sales and marketing efforts. Consulting expenses rose as
additional advisory services were required to support Ceapro's international
customers on existing and new product sales, and new distribution and
licensing agreements.

Royalties

$000s                                               2004    2003  Change
-------------------------------------------------------------------------
Royalty interest units                               203     121
AVAC royalty                                          74      58
-------------------------------------------------------------------------
Total royalties expenses                             277     179     55%
-------------------------------------------------------------------------

Royalties expense increased 55% year-over-year. This increase is related
to the timing of royalties earned by investors who participated in the Royalty
Interest and Royalty Income Unit offerings completed throughout 2003, and the
higher royalties earned by AVAC Ltd. on eligible product sales due to a shift
in product sales mix.

Quarterly Information

The following selected financial information is derived from Ceapro's
unaudited quarterly financial statements for each of the last eight quarters,
all of which cover periods of three months.

$000s
 except
 per                   2004                            2003
 share    ------------------------------- -------------------------------
 data         Q4      Q3      Q2      Q1      Q4      Q3      Q2      Q1
-------------------------------------------------------------------------
Total
 revenues    469     414     975     561     590     485     865     484
Net income
 (loss)      (78)   (361)    (71)    113    (139)    331     220      30
Basic
 income
 (loss)
 per
 share    (0.002) (0.010) (0.002)  0.003  (0.004)  0.008   0.007   0.001
Diluted
 income
 (loss)
 per
 share    (0.002) (0.010) (0.002)  0.003  (0.004)  0.007   0.007   0.001

Ceapro's quarterly results fluctuate primarily due to variations in the
timing and proceeds of various public and private income offerings, product
sales, and royalty and license fees. In 2003 and 2004, the results are
negatively impacted by foreign exchange due to the significant strengthening
of the Canadian dollar.

Outlook

On March 31, 2005, we completed a private placement share offering of
682,666 Units, for aggregate gross proceeds of $204,800. We continue to pursue
additional financings to fund on-going working capital requirements and to
secure the financial resources required to support the expected increases in
the volume of sales of existing products, the introduction of new products to
existing and new markets, and the development of new technology. Our operating
plans will continue to be implemented in a measured and responsible manner and
we caution that additional investments required to continue to expand the
business and product lines may affect the pace of growth.
While we incurred a loss for the year, we remain positive in our business
outlook. A number of recent initiatives should result in increased sales in
2005 and beyond. Our order book is beginning to fill for the second quarter,
evidence that active ingredient sales are beginning to recover as the
reformulated beta-glucan product is introduced to customers and incorporated
into new or existing product formulations. We have made strides in the
commercialization of CeaProve(TM), our diabetes diagnostic product,
identifying new applications in the areas of diabetes monitoring and drug
dosage determination. The signing of new distribution agreements for
veterinary therapeutic products in Asia and Canada, the development of new
veterinary therapeutic products and their addition to the Japan distribution
agreement all pave the way for increased sales throughout 2005.
Ceapro advises that its audited financial statements for the year ended
December 31, 2004, and accompanying management's discussion and analysis, has
been filed with securities regulators and is available on www.sedar.com. The
Company's annual report will be mailed to shareholders on or about May 2,
2005. The annual meeting of shareholders will take place in Edmonton, on
June 1, 2005.

About Ceapro Inc.

Ceapro Inc., an innovation-driven biotechnology company, develops and
commercializes organic products for medical, cosmetic, and animal health
industries using proprietary technology and natural, renewable resources.
Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing
Companies for 2004 and 2005 and is one of Profit Magazine's Next 100
Companies. Ceapro is also the recipient of the ASTech Award for Outstanding
Commercial Achievement for companies with annual sales of less than
$25 million. Ceapro's shares trade on the TSX Venture Exchange under the
symbol CZO. To learn more about Ceapro, log on to our website at
www.ceapro.com. Shares Outstanding: 36,355,950, Recent Close: $0.30.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the     
forward-looking statements contained herein are reasonable, it can give no
assurance that the Company's expectations are correct. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement.


Consolidated Balance Sheets
Unaudited

                                                December 31  December 31
                                                       2004         2003
-------------------------------------------------------------------------
ASSETS

CURRENT ASSETS
  Cash                                          $    96,266  $   248,443
  Accounts receivable                               375,160      514,154
  Inventories                                       345,424      115,556
  Prepaid expenses and deposits                      66,473       29,971
  Deferred charges                                   50,000            -
-------------------------------------------------------------------------

                                                    933,323      908,124

RESTRICTED CASH FOR THE PURCHASE OF PROPERTY
 AND EQUIPMENT                                       64,430            -

PROPERTY AND EQUIPMENT                              720,067      347,188
-------------------------------------------------------------------------

                                                $ 1,717,820  $ 1,255,312
-------------------------------------------------------------------------
-------------------------------------------------------------------------

LIABILITIES

CURRENT LIABILITIES
  Accounts payable and accrued liabilities      $   713,201  $   433,594
  Deferred revenue                                   80,000            -
  Callable debt                                     122,296      159,683
  Current portion of convertible debentures          17,510        9,436
  Current portion of long-term debt                  28,234       40,000
  Current portion of royalties payable              104,498      102,029
-------------------------------------------------------------------------

                                                  1,065,739      744,742

CONVERTIBLE DEBENTURES                                    -       17,510

LONG-TERM DEBT                                      471,766        4,832

ROYALTIES PAYABLE                                    66,249      105,998
-------------------------------------------------------------------------

                                                  1,603,754      873,082
-------------------------------------------------------------------------

SHAREHOLDERS' EQUITY

SHARE CAPITAL                                     1,995,443    1,855,823
CONTRIBUTED SURPLUS                                 121,997      132,044
DEFICIT                                          (2,003,374)  (1,605,637)
-------------------------------------------------------------------------

                                                    114,066      382,230
-------------------------------------------------------------------------

                                                $ 1,717,820  $ 1,255,312
-------------------------------------------------------------------------
-------------------------------------------------------------------------



Consolidated Statements of Income (Loss) and Deficit
Unaudited
                         Twelve Months Ended         Quarters Ended
                             December 31               December 31
                             2004         2003         2004         2003
-------------------------------------------------------------------------

Revenue
  Sales               $ 1,956,961  $ 2,218,262  $   299,206  $   577,363
  Cost of goods sold    1,022,831      928,115      186,055      192,667
-------------------------------------------------------------------------

  Gross margin            934,130    1,290,147      113,151      384,696
  Royalties, licenses,
   and product
   development fees       462,758      206,098      170,000       12,960
-------------------------------------------------------------------------

                        1,396,888    1,496,245      283,151      397,656
-------------------------------------------------------------------------

Expenses
  General and
   administration         833,346      756,716      199,665      191,131
  Sales and marketing     130,578      230,701       34,787       72,515
  Royalties               277,149      179,475       51,499       60,761
  Interest on
   convertible
   debentures and
   other                    7,383       32,149        1,608        1,990
  Interest on
   long-term debt          21,120       15,624       10,537        5,028
  Amortization             91,962       59,960       29,481       21,721
-------------------------------------------------------------------------

                        1,361,538    1,274,625      327,577      353,146
-------------------------------------------------------------------------

Income (loss) from
 operations                35,350      221,620      (44,426)      44,510
-------------------------------------------------------------------------

Other income (expenses)
  Other income
   (expenses)            (118,211)     574,162       20,909      (56,630)
  Research and product
   development           (302,487)    (353,744)     (54,322)    (126,304)
  Loss on disposal of
   property and
   equipment              (12,389)           -            -            -
-------------------------------------------------------------------------

                         (433,087)     220,418      (33,413)    (182,934)
-------------------------------------------------------------------------

Income (loss) before
 income taxes            (397,737)     442,038      (77,839)    (138,424)

Income taxes
  Current                 654,483      275,437            -            -
  Reduction as a
   result of applying
   non-capital losses
   carried forward
   against the
   current period's
   taxable income        (654,483)    (275,437)           -            -
-------------------------------------------------------------------------

NET INCOME (LOSS) FOR
 THE PERIOD              (397,737)     442,038      (77,839)    (138,424)

Deficit at beginning
 of period             (1,605,637)  (2,047,675)  (1,925,535)  (1,467,213)
-------------------------------------------------------------------------

DEFICIT AT END OF
 PERIOD               $(2,003,374) $(1,605,637) $(2,003,374) $(1,605,637)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Net income (loss) per
 share :
  Basic               $    (0.011) $     0.014  $    (0.002) $    (0.004)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
  Diluted             $    (0.011) $     0.013  $    (0.002) $    (0.004)
-------------------------------------------------------------------------



Consolidated Statements of Cash Flows
Unaudited
                         Twelve Months Ended         Quarters Ended
                             December 31               December 31
                             2004         2003         2004         2003
-------------------------------------------------------------------------

OPERATING ACTIVITIES
  Net income (loss)
   for the period     $  (397,737) $   442,038  $   (77,839) $  (138,424)
    Items not affecting
     cash
      Amortization         91,962       59,960       29,481       21,721
      Loss on disposal
       of property and
       equipment           12,389            -            -            -
      Conversion of
       debentures,
       loans, and
       interest to
       royalty
       interest                 -     (304,123)           -            -
      Stock-based
       compensation        19,006       89,872          572        9,587
-------------------------------------------------------------------------

                         (274,380)     287,747      (47,786)    (107,116)

    Changes in
     non-cash working
     capital items
      Accounts
       receivable         138,994     (239,286)    (243,171)     (45,775)
      Inventories        (229,868)     (58,739)      18,359      (61,285)
      Prepaid expenses
       and deposits       (36,502)     (15,212)     (28,958)      (7,498)
      Deferred charges    (50,000)           -      (50,000)           -
      Accounts payable
       and accrued
       liabilities        279,607       96,061      154,681       40,984
      Deferred revenue     80,000            -       80,000            -
-------------------------------------------------------------------------

                          (92,149)      70,571     (116,875)    (180,690)
-------------------------------------------------------------------------

INVESTING ACTIVITIES
    Purchase of
     property and
     equipment           (477,230)    (133,637)    (149,950)      (8,602)
    Restricted cash
     for purchase of
     property and
     equipment            (64,430)           -      (64,430)           -
-------------------------------------------------------------------------

                         (541,660)    (133,637)    (214,380)      (8,602)
-------------------------------------------------------------------------

FINANCING ACTIVITIES
    Increase
    (decrease) in
     long-term debt       417,781     (112,019)     264,106      (23,994)
    Increase in share
     capital              111,131      354,755       67,544      235,895
    Decrease in
     convertible
     debentures           (10,000)     (15,000)           -            -
    Increase
     (decrease) in
     royalties
     payable              (37,280)      58,381       (7,734)      11,732
-------------------------------------------------------------------------

                          481,632      286,117      323,916      223,633
-------------------------------------------------------------------------

Increase (decrease)
 in cash                 (152,177)     223,051       (7,339)      34,341
Cash at beginning of
 period                   248,443       25,392      103,605      214,102
-------------------------------------------------------------------------

CASH AT END OF
 PERIOD               $    96,266  $   248,443  $    96,266  $   248,443
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Supplementary
 information:
    Interest paid     $    26,300  $    55,018  $    12,067  $     1,686
    Royalties paid    $   312,502  $    79,271  $    59,233  $    36,080



>>
%SEDAR: 00010110E

Ceapro on 6ix

Earlier from Ceapro

Later from Ceapro

All Ceapro news releases